Nelarabine

Nelarabine

File:Nelarabine.svg
Clinical data
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Intravenous
ATC code	L01BB07 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	n/a
Protein binding	<25%
Metabolism	By adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Elimination half-life	30 minutes (nelarabine) 3 hours (ara-G)
Excretion	Renal
Identifiers
IUPAC name (2R,3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)- 5-(hydroxymethyl)oxolane-3,4-diol
CAS Number	121032-29-9
PubChem CID	3011155
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H15N5O5
Molar mass	297.268 g/mol

WikiDoc Resources for Nelarabine
Articles
Most recent articles on Nelarabine Most cited articles on Nelarabine Review articles on Nelarabine Articles on Nelarabine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nelarabine Images of Nelarabine Photos of Nelarabine Podcasts & MP3s on Nelarabine Videos on Nelarabine
Evidence Based Medicine
Cochrane Collaboration on Nelarabine Bandolier on Nelarabine TRIP on Nelarabine
Clinical Trials
Ongoing Trials on Nelarabine at Clinical Trials.gov Trial results on Nelarabine Clinical Trials on Nelarabine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nelarabine NICE Guidance on Nelarabine NHS PRODIGY Guidance FDA on Nelarabine CDC on Nelarabine
Books
Books on Nelarabine
News
Nelarabine in the news Be alerted to news on Nelarabine News trends on Nelarabine
Commentary
Blogs on Nelarabine
Definitions
Definitions of Nelarabine
Patient Resources / Community
Patient resources on Nelarabine Discussion groups on Nelarabine Patient Handouts on Nelarabine Directions to Hospitals Treating Nelarabine Risk calculators and risk factors for Nelarabine
Healthcare Provider Resources
Symptoms of Nelarabine Causes & Risk Factors for Nelarabine Diagnostic studies for Nelarabine Treatment of Nelarabine
Continuing Medical Education (CME)
CME Programs on Nelarabine
International
Nelarabine en Espanol Nelarabine en Francais
Business
Nelarabine in the Marketplace Patents on Nelarabine
Experimental / Informatics
List of terms related to Nelarabine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.

Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Complete responses have been achieved with this medication.

It is marketed as Arranon by GlaxoSmithKline.

External links

• The Childrens Oncology Group (COG)
• GlaxoSmithKline
• American Cancer Society